Study on new migraine drugs in real life
Part of Brain & nervous system, Pain clinical trials.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with migraine by a doctor
- You are prescribed one of these migraine drugs: erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant, or rimegepant
- You are willing to sign a consent form to participate
- You do not have a different type of headache disorder (like tension headache or cluster headache)
- You do not have a severe active psychiatric condition or thinking/memory problems that would prevent you from understanding the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at the chemical changes in the blood of people with migraine. It aims to better understand the disease and may help find new treatments. You may qualify if you have episodic or chronic migraine and have not tried CGRP-targeting drugs.
This study is building a database to learn more about migraine drugs. It may help researchers find better treatments for people with episodic or chronic migraine.
This study looks for new biological markers in people whose migraines don't respond to standard treatments. It aims to better understand why some migraines are hard to treat and may help guide future therapies.
This trial tests two new migraine medicines, rimegepant and zavegepant, given to people in the emergency department to see how well they work for stopping a migraine headache quickly.
This study tracks the health of pregnant women with migraine who take Aimovig. It helps doctors understand if the medicine is safe to use during pregnancy.
This study tests a CGRP-blocking antibody to see how it affects migraine symptoms and the body’s automatic (involuntary) nerve functions. It may help people with migraine who have already tried several preventive medicines.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.